Multinational, Multicenter, Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain

Trial Profile

Multinational, Multicenter, Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2016

At a glance

  • Drugs GRC 15300 (Primary)
  • Indications Neuropathic pain
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms ALCHEMILLA
  • Most Recent Events

    • 01 May 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Dec 2012 Planned End Date changed from 1 Mar 2013 to 1 May 2013 as reported by ClinicalTrials.gov.
    • 22 Feb 2012 Actual initiation date (Nov 2011) added and additional locations (Czech Republic, Hungary, Multinational, Poland, Russia, Slovakia, Ukraine) added as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top